Pacific Biosciences Of California (PACB) Liabilities and Shareholders Equity (2010 - 2026)

Pacific Biosciences Of California's Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $782.4 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 9.11% year-over-year to $782.4 million; the TTM figure through Mar 2026 stood at $3.2 billion (down 37.11% YoY), while the FY2025 annual figure was $784.1 million, down 37.79% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $782.4 million, roughly flat from $784.1 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.9 billion in Q1 2022, with the low at $782.4 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $1.7 billion (2024), against an average of $1.5 billion.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity surged 56688.92% in 2022, then tumbled 48.45% in 2025.
• Pacific Biosciences Of California's Liabilities and Shareholders Equity stood at $1.8 billion in 2022, then fell by 1.19% to $1.7 billion in 2023, then declined by 27.81% to $1.3 billion in 2024, then sank by 37.79% to $784.1 million in 2025, then slipped by 0.22% to $782.4 million in 2026.
• Business Quant data shows PACB's Liabilities and Shareholders Equity at $782.4 million in Q1 2026, $784.1 million in Q4 2025, and $803.2 million in Q3 2025.